Trial
NCT03678506
Apixaban for Extended Anticoagulation (APIDULCIS)
Phase IVTERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Arianna Anticoagulazione Foundation
Collaborators
—
Condition
Venous Thromboembolism
Intervention
Apixaban
Why stopped
The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval \[CI\], 4.5-11.2)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-24